SALT LAKE CITY -– January 5, 2024 – BioUtah, the trade association, common voice and flag bearer for Utah’s life sciences community, today announced that it will participate in the J.P. Morgan 42nd Annual Healthcare Conference, January 8-11, 2024. BioUtah President and CEO, Kelvyn Cullimore, will attend on behalf of the association, representing its member companies and the state’s life sciences industry in general.
"Utah's life sciences industry is a good news story,” said Cullimore. “The J.P. Morgan gathering provides us an extraordinary opportunity to get the word out about our dynamic innovation hub and business-friendly state.”
Cullimore will engage with industry leaders and investors to promote Utah’s life sciences ecosystem, which includes medical technology, diagnostics, biotechnology and pharmaceutical companies. A recent study by the University of Utah Kem C. Gardner Policy Institute shows that Utah consistently ranks in the top three states for growth in the life sciences. In Utah, the sector accounts for $22.6 billion in GDP and approximately 180,000 jobs.
A number of Utah life sciences companies, Halia Therapeutics, Merit Medical Systems, Myriad Genetics, Recursion and Thermo Fisher Scientific, will present at the conference, with Halia presenting at the Biotech Showcase.
The J.P. Morgan Healthcare Conference is considered the largest investment symposium in the industry.
